Navigation Links
72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds
Date:5/13/2008

Foamix Offers New Intravaginal Foam Technology with Improved Usability &

Compliance

NESS ZIONA, Israel, May 13 /PRNewswire/ -- Despite the high incidence of women's health conditions that require intra-vaginal drug delivery and the abundance of intravaginal creams, gels and ovules, a recent survey found that an alarming majority of women find their current treatment options "unacceptable" or "intolerable". The survey, conducted by Elixir-Applied Researches for Foamix, polled more than 200 women.

Findings show that the majority of females who have used intravaginal drugs find them dissatisfying because these products leak out of the vagina following treatment (72%), because of irritation, itch or bad smell (60%), or simply because they are inconvenient to use (58%). 82% of the panellists opined that they would trade their current medication for a new form that does not leak; and 65% would prefer a product that does not cause irritation, itch or bad smell.

Foamix develops foam delivery systems for intravaginal administration that expand gently in the vaginal cavity and evenly cover the entire vaginal surface for efficient treatment. The Foamix foams are administered in small and accurate amounts, (using metered dose valves). They are bioadhesive to reduce dosing frequency and are constituted of non-irritating ingredients. Notably, the Foamix foams are fully retained inside the vagina, resulting in non leakage and enhanced efficacy.

"It seems the majority of women are dissatisfied with the current intravaginal treatment options. Treatment inconvenience is known to result in poor treatment compliance and there is therefore still a need for new drug delivery systems that can be easily administered, enable adherence of drugs to the vaginal surface and do not leak out or cause irritation," says Arie Yeshaya, M.D., Senior Gynecologist at Rabin Medical Center, Israel (affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel); and a women's health consultant to Foamix.

"The Foamix foam concept hits right on the spot of the drawbacks of current treatments," he adds.

"The Foamix intravaginal foam platform was developed with these difficulties in mind. We are working with major pharma companies to co-develop and market new intravaginal and dermal foam formulations," says Dr. Dov Tamarkin, CEO of Foamix Ltd.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix is currently collaborating with 10 pharmaceutical companies on 11 projects in the development of proprietary dermal and intravaginal drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation. Foamix holds 4 US patents and has 64 US patents pending, with further filings worldwide.

For additional information please visit http://www.foamix.co.il

Press inquiries:

Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
3. KGI and Smith College Establish Leadership Forum for Women in Bioscience
4. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
5. ABCs Private Practice Inaccurately Portrays Serious Womens Health Condition
6. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
7. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
8. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
9. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
10. Collaboration Sparks Creation of New Grand Rapids Laboratory Focused on Womens Health
11. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea monster her father ... found a sea turtle entangled in the lines of one of his lobster pots. He ... because no one could remember ever seeing one so large so close to shore. After ...
(Date:12/6/2016)... Texas , Dec. 6, 2016 The ... for its adoption of arnica ( Arnica montana ... support to ABC,s HerbMedPro database, a ... important scientific and clinical research data on the ... popular herbs. Naturopathica, a wellness company ...
(Date:12/6/2016)... 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... quarter and fiscal year ended September 30, 2016. ... , , ... and diagnostics company that develops and commercializes proprietary technologies and products ... Achieved revenues of $1.4 million more than tripling prior years ...
(Date:12/6/2016)... PA (PRWEB) , ... December ... ... part of the Almac Group, the world’s largest privately-held contract pharmaceutical development ... with inVentiv Health, a leading biopharma outsourcing company combining a leading CRO ...
Breaking Biology Technology:
(Date:12/6/2016)... Ind. , Dec. 6, 2016  Zimmer Biomet Holdings, ... it has priced an offering of €500.0 million principal amount ... million principal amount of its 2.425% senior unsecured notes due ... expected to occur on December 13, 2016, subject to the satisfaction ... an annual basis. The ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):